Traversa Founder Says Multi-Targeting Approach Key to RNAi-Based Cancer Drugs

Last week, Traversa Therapeutics founder Steve Dowdy presented data at the annual meeting of the American Society of Gene and Cell Therapy in Washington, DC, describing his lab's development of an siRNA cocktail against glioblastoma that incorporates a proprietary delivery technology.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.